These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23998688)

  • 1. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Holmäng S; Babjuk M; Fajkovic H; Seitz C; Klatte T; Pycha A; Bachmann A; Scherr DS; Shariat SF
    Eur Urol; 2014 Jan; 65(1):201-9. PubMed ID: 23998688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.
    Rink M; Zabor EC; Furberg H; Xylinas E; Ehdaie B; Novara G; Babjuk M; Pycha A; Lotan Y; Trinh QD; Chun FK; Lee RK; Karakiewicz PI; Fisch M; Robinson BD; Scherr DS; Shariat SF
    Eur Urol; 2013 Sep; 64(3):456-64. PubMed ID: 23206854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
    Kluth LA; Xylinas E; Crivelli JJ; Passoni N; Comploj E; Pycha A; Chrystal J; Sun M; Karakiewicz PI; Gontero P; Lotan Y; Chun FK; Fisch M; Scherr DS; Shariat SF
    J Urol; 2013 Aug; 190(2):480-6. PubMed ID: 23376707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients.
    Mitra AP; Skinner EC; Schuckman AK; Quinn DI; Dorff TB; Daneshmand S
    Urol Oncol; 2014 Jan; 32(1):52.e1-9. PubMed ID: 24239476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis.
    Mitra AP; Bartsch CC; Bartsch G; Miranda G; Skinner EC; Daneshmand S
    Urol Oncol; 2014 Feb; 32(2):117-27. PubMed ID: 23477878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Babjuk M; Bachmann A; Scherr DS; Shariat SF
    Urol Oncol; 2014 Jan; 32(1):49.e7-14. PubMed ID: 24140245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of TaG1 non-muscle-invasive bladder cancer.
    Olivier Bosset P; Neuzillet Y; Paoletti X; Molinie V; Botto H; Lebret T
    Urol Oncol; 2015 Jan; 33(1):20.e1-20.e7. PubMed ID: 25282704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy.
    Xylinas E; Rink M; Robinson BD; Lotan Y; Babjuk M; Brisuda A; Green DA; Kluth LA; Pycha A; Fradet Y; Faison T; Lee RK; Karakiewicz PI; Zerbib M; Scherr DS; Shariat SF
    Eur J Cancer; 2013 May; 49(8):1889-97. PubMed ID: 23466126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.
    Thomas F; Noon AP; Rubin N; Goepel JR; Catto JW
    Eur Urol; 2013 Jan; 63(1):145-54. PubMed ID: 22985746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
    Kluth LA; Xylinas E; Rieken M; El Ghouayel M; Sun M; Karakiewicz PI; Lotan Y; Chun FK; Boorjian SA; Lee RK; Briganti A; Rouprêt M; Fisch M; Scherr DS; Shariat SF
    BJU Int; 2014 Mar; 113(3):393-8. PubMed ID: 24053618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
    May M; Bastian PJ; Brookman-May S; Fritsche HM; Tilki D; Otto W; Bolenz C; Gilfrich C; Trojan L; Herrmann E; Moritz R; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Wieland WF; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
    Urol Oncol; 2013 Oct; 31(7):1141-7. PubMed ID: 22056404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.